Clinical Trial Search

Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants

Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects

Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants

Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants

Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants

Primary: Geometric Mean Anti-typhoid Vi Antibody Concentrations — 6.37; 5.6; 134; 153 El.U/mL

Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants

Primary: Percentage of Participants With Protective Titres to PCV13 Serotypes Post-immunization With PCV13+PPV23 — 40; 22 Participants

Primary: Change in Vaccine Hesitancy Scores Pre- and Post-Intervention. — -0.4 units on a scale

Primary: Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) — 23; 27; 25; 10 Participants

Primary: Primary Outcome — 26432; 19352 participants vaccinated out of all — p=<0.05

Primary: Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity — 0; 0; 0 Participants

Primary: Vacc-4x Effect on Viral Load Set-point — 38455.0; 40088.8; 45253.9; 47336.8 Copies/mL

Primary: Child Immunization Status at 19 Months, 0 Days of Age Characterized as Percent Days Under-immunized (DUI) — 32; 24 percentage of days under-immunized — p=0.9

Primary: Percentage of Participants Vaccinated With PR5I With Acceptable Antibody (Ab) Response to Haemophilus Influenzae Type b, Diphtheria, Tetanus, and Poliovirus Types 1, 2 &…

Primary: Safety: Grade 3 Adverse Events — 1; 0 participants

Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…

Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants

Primary: Geometric Mean Titer (GMT) of Toxin Neutralizing Antibody (TNA) 50% Neutralization Factor (NF50) at Day 64 — 0.765; 0.741; 0.716; 0.330 Titer (TNA NF50)

Primary: Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza — 28; 56; 35 participants

Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants

Primary: Percentage of Women With Reduced Number of Concerns Immediately Post-counseling in the Intervention Arm — 51.72 percentage of women

Primary: Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value — 729; 374; 836; 428 subjects

Primary: Number of Subjects Reporting Fever — 24; 32 Subjects

Primary: Percentage of Participants With Ebola Virus Glycoprotein (GP-EBOV) Antibody Response — 40.9; 75.7; 81.1; 2.7 percentage of participants — p=<.001

Primary: Qualitative Seroresponsiveness to Hepatitis B Surface Antigen — 41; 52; 6; 3 Participants — p=0.2954

Primary: Hepatitis A Virus (HAV) Seroconversion Rate, i.e. the Percentage of Subjects Who Were Seronegative at Baseline and Developed Seropositive at Month 7 After Administration…

Primary: Number of Human Blood Samples Collected for Conversion Into Serum at Day -83 — 5578; 1936 Blood samples

Primary: Toxicity — 1; 1; 6; 1 participants